AstraZeneca agrees to buy US FDA Priority Review
22 August 2019 07:00 BST AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval. The transaction is subject to clearance under the Hart-Scott